Medication info

TDS Pregabalin Capsule 75 mg

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
TDS Pharm Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow in color.
Packaging
30 capsules/bottle, 60 capsules/bottle, 100 capsules/bottle
Approval status
Expired

MFDS item code 201907840 · Approved 2019.11.08

This product's status changed to Expired on 2024.11.08. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function (see “5. Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see “4. Discontinuation”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. Start with 75 mg twice daily (150 mg daily); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies were also conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 to 17 years: Use is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
TDS Pharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It also serves as an adjunctive therapy for patients with epilepsy experiencing partial seizures. It is effective in alleviating pain associated with fibromyalgia. Thus, it is effective for various neurological disorders and helps improve the quality of life of patients.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function (see “5. Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see “4. Discontinuation”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. Start with 75 mg twice daily (150 mg daily); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies were also conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 to 17 years: Use is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so any changes in mood or behavior should be carefully monitored during treatment. Do not use if you are allergic to any ingredients in this medication, and patients with certain genetic conditions like lactose intolerance should also avoid it. Diabetic patients may need to adjust the dosage of their blood sugar-lowering medications due to weight gain after using this medication. If symptoms of angioedema such as swelling of the face or neck occur, discontinue use immediately. Elderly patients should be cautious as this medication may increase the risk of dizziness or drowsiness, leading to a higher risk of falls. This medication may temporarily blur vision or cause changes in vision; consult a doctor if these symptoms occur. Abruptly stopping this medication may result in withdrawal symptoms such as insomnia, headache, or anxiety; it should be tapered according to a doctor's instructions. Because of the risk of drug abuse, patients with a history of mental health issues should be particularly cautious, and any signs of abuse should be reported to healthcare personnel immediately. Patients with heart disease or congestive heart failure should use this medication cautiously. Using this medication in conjunction with opioid analgesics may enhance CNS depressant effects, leading to risks such as difficulty breathing. Pregnant women should avoid this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Breastfeeding women should consult a doctor before taking this medication, as it may transfer to breast milk and affect the baby. It is advisable to avoid activities requiring concentration, such as driving or operating dangerous machinery, until dizziness or drowsiness has subsided after taking this medication. In cases of overdose, symptoms such as confusion, drowsiness, or depression may occur, and treatment such as dialysis may be necessary if required. This medication should be stored out of reach of children and should not be transferred to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 198 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • pain
  • sweating
  • drug misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • reduced libido
  • insomnia
  • depersonalization
  • sexual dysesthesia
  • restlessness
  • anxiety
  • mood swings
  • emotional reduction
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • coordination issues
  • balance disorders
  • amnesia
  • attention deficits
  • memory impairments
  • tremors
  • speech disorders
  • sensory abnormalities
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reduced reflexes
  • motor abnormalities
  • psychomotor agitation
  • orthostatic dizziness
  • hypersensitivity
  • burning sensations
  • action tremors
  • syncope
  • confusion
  • motor retardation
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • blurred vision
  • double vision
  • peripheral vision loss
  • visual field disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eye swelling
  • decreased visual acuity
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • visual brightness
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • shortness of breath
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensation reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling drunk
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • reduced platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • reduced white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme
  • delirium
  • paralysis
  • affective disorders
  • agitation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture. Additionally, it is best to keep it in a location that avoids extreme temperatures, maintaining a room temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow in color.

Package unit

30 capsules/bottle, 60 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.